JLE

Hépato-Gastro & Oncologie Digestive

MENU

Role of immunotherapy and new targeted therapies in the treatment of HER2-advanced œsophageal adenocarcinoma Volume 30, supplement 4, September 2023

Figures


  • Figure 1
Authors
CHU de Toulouse, Institut Universitaire de Cancérologie (IUCT) Rangueil/Larrey, Service d’Oncologie médicale digestive, 1 avenue du Pr J. Poulhès, Toulouse Cedex 9
* Correspondance : R. Guimbaud

Advanced gastric cancer remains a malignant tumor with poor prognosis, the majority of cases still diagnosed at an advanced stage.

Apart from human epidermal growth factor receptor 2 (HER2) targeting, which only concerns 20% of advanced oesophageal adenocarcinomas, the treatment of advanced cases has been restricted, until recently, to cytotoxic chemotherapy and supportive care, leading to a poor median survival, barely reaching one year.

Recently, however, major therapeutic changes have emerged with immune checkpoint inhibitor immunotherapies, leading to a definite improvement in results and a change in our practices. In addition, after many years of failure of non-HER2 targeted therapies in this disease, new therapeutic targets have emerged to broaden the therapeutic panel.